CC-671

• CAT Number: I013006
• CAS Number: 1618658-88-0
• Molecular Formula: C₂₈H₂₈N₆O₄
• Molecular Weight: 512.56
• Purity: ≥95%
• Target: CDK
• Solubility: DMSO
• Storage: Store at -20°C
• IUPAC Name: 4-[[4-cyclopentyloxy-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-3-methoxy-N-methylbenzamide
• InChI: InChI=1S/C28H28N6O4/c1-15-31-21-10-8-16(12-23(21)37-15)19-14-30-25-24(19)27(38-18-6-4-5-7-18)34-28(33-25)32-20-11-9-17(26(35)29-2)13-22(20)36-3/h8-14,18H,4-7H2,1-3H3,(H,29,35)(H2,30,32,33,34)
• InChIKey: CWJLAVRXVFHDSJ-UHFFFAOYSA-N
• SMILES: CC1=NC2=C(O1)C=C(C=C2)C3=CNC4=C3C(=NC(=N4)NC5=C(C=C(C=C5)C(=O)NC)OC)OC6CCCC6

CC-671（Cat No.:I013006）is a potent, selective inhibitor of multiple kinases, including cyclin-dependent kinase 9 (CDK9) and poly (ADP-ribose) polymerase (PARP). By inhibiting CDK9, it disrupts transcriptional elongation and reduces the expression of genes essential for cancer cell survival. Its PARP inhibition enhances DNA damage and impairs repair mechanisms, leading to apoptosis in cancer cells. CC-671 is being explored in oncology research for its potential to treat cancers with defective DNA repair pathways. Its dual mechanism of action makes it a promising candidate for combination cancer therapies.

Reference

[1]. Riggs JR, et al. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatmentof Triple Negative Breast Cancer Initiated from a Phenotypic Screen. J Med Chem. 2017 Nov 9;60(21):8989-9002.